chr18-45838826-C-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_213602.3(SIGLEC15):c.605C>A(p.Pro202Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000162 in 1,562,904 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Synonymous variant affecting the same amino acid position (i.e. P202P) has been classified as Likely benign.
Frequency
Consequence
NM_213602.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SIGLEC15 | NM_213602.3 | c.605C>A | p.Pro202Gln | missense_variant | 4/6 | ENST00000389474.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SIGLEC15 | ENST00000389474.8 | c.605C>A | p.Pro202Gln | missense_variant | 4/6 | 1 | NM_213602.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000776 AC: 118AN: 152118Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000110 AC: 18AN: 163456Hom.: 0 AF XY: 0.000111 AC XY: 10AN XY: 90486
GnomAD4 exome AF: 0.0000950 AC: 134AN: 1410668Hom.: 1 Cov.: 30 AF XY: 0.0000887 AC XY: 62AN XY: 698742
GnomAD4 genome AF: 0.000782 AC: 119AN: 152236Hom.: 0 Cov.: 33 AF XY: 0.000820 AC XY: 61AN XY: 74426
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 02, 2021 | The c.605C>A (p.P202Q) alteration is located in exon 4 (coding exon 4) of the SIGLEC15 gene. This alteration results from a C to A substitution at nucleotide position 605, causing the proline (P) at amino acid position 202 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at